An interventional study of Multiple Fraction PBI and Single Fraction PBI in Breast Cancer Early Stage Breast Cancer (Stage 1-3), sponsored by British Columbia Cancer Agency. Recruiting at 1 site in Canada. Open to female participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by British Columbia Cancer Agency · Not applicable, Interventional, and Treatment
Among 20 studies in Breast Neoplasms by British Columbia Cancer Agency — 4 open to participants now, 6 under way, none of them phase 3. Breast Neoplasms · British Columbia Cancer Agency.
Among the 20 studies in Breast Neoplasms by British Columbia Cancer Agency, this one is the 8th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2026, is one of 10 with no phase, and was the 19th registered.
14,825 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →4 of the 20 studies in Breast Neoplasms by British Columbia Cancer Agency are open now, in 1 country. Recruiting first, the newest first:
British Columbia Cancer Agency · Sites in Canada
British Columbia Cancer Agency · Sites in Canada
British Columbia Cancer Agency · Sites in Canada
By country, each count listing its studies:
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 40 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 60 is below the median of 72 across 10,896 interventional studies indexed under Breast Neoplasms.
Median enrollment 50 across the 17 interventional studies, 80 across the 3 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
British Columbia Cancer Agency is the lead sponsor of 152 studies on the registry; 33 are open to participants now.
2 of the studies in Breast Neoplasms by British Columbia Cancer Agency that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06665178British Columbia Cancer AgencyGenomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer | 2027-05-01 |
| NCT04273061British Columbia Cancer AgencyInvestigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity | 2027-10 |
Among the 20 studies in Breast Neoplasms by British Columbia Cancer Agency, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Partial Breast Irradiation (PBI) is a targeted radiation approach commonly administered post-lumpectomy, specifically targeting the tumour bed. This targeted therapy reduces the exposure to other nearby tissues such as lungs, heart, and chest wall. However, traditional PBI treatment involves lengthy multiple fraction courses which presents a burden to patients from rural and remote communities, who must travel long distances to receive high quality cancer care. The purpose of this study is to compare single fraction (SF) PBI vs. multiple fraction (MF) PBI.
Radiation can be delivered in multiple fractions, or doses, and can take up to several weeks or months of treatment depending on the type of cancer. Radiation can also be offered in a single fraction. Both techniques have evidence for use in clinical care. Multiple fraction is offered to reduce the amount of radiation given at a single time that could reduce late toxicities. However, single fraction radiotherapy is more cost-effective and saves patient time. With this trial, we will compare single fraction vs. multiple fraction PBI in regards to their impact on quality of life, rates of provider and participant reported toxicities, and local control.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant is judged able to:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For participants randomized to Arm 1, PBI will be delivered with a dose of 26 Gy in 5 daily fractions.
Radiation: Multiple Fraction PBI
For participants randomized to Arm 2, PBI will be delivered in a single fraction with a dose of 13 Gy.
Radiation: Single Fraction PBI
Participants randomized to Arm 1 will receive PBI with a dose of 26 Gy in 5 daily fractions.
Participants randomized to Arm 2 will receive PBI in a single fraction with a dose of 13 Gy.
Number of participants accrued
Number of participants who sign consent to be randomized to 1 vs 5 fractions of radiotherapy for PBI over a 2 year period
Time frame: 2 years
Time from CT simulation to plan approval
Measured as the time from the day of CT simulation to the date of plan approval.
Time frame: Baseline
2-Year Local Control Rates
Absence of ipsilateral in-breast recurrence, defined as histologic evidence of invasive or in situ breast cancer in the ipsilateral breast 2 years post-treatment
Time frame: 6 weeks, 6 months, 12, months, 18 months, and 24 months post-treatment
Quality of life assessed using the POSI-Breast questionnaire
Prospective Outcomes and Support Initiative (POSI) for Breast Data will be used to measure and compare the quality of life of participants in both arms.
Time frame: Baseline, 6 weeks, 6 months, 12 months, 18 months, and 24 months post treatment
Rates of provider-rated toxicities: Occurrences of adverse events as measured by CTCAE
Participant-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Data will be used to measure and compare participant-reported toxicities in both arms.
Time frame: Baseline, 6 weeks, 6 months, 12 months, 18 months, and 24 months post treatment
Participant-reported toxicities
Occurrences of adverse events as measured by PRO-CTCAE
Time frame: Baseline, 6 weeks, 6 months, 12, months, 18 months, and 24 months post-treatment
Overall Survival (OS)
Time from randomization to death from any cause, or last follow-up, whichever occurs first.
Time frame: Approximately at the end of year 2 (study completion)
Progression-Free Survival (PFS)
Time from randomization to disease progression at any site, death, or last follow-up, whichever occurs first.
Time frame: 6 weeks, 6 months, 12 months, 18 months, and approximately at the end of 24 months
Started Jun 2026 (actual). Primary completion is estimated for Dec 2029, 42 months after the start.
Of 2,661 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 42 months is above that.
Counting every sponsor, half of 2,771 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
British Columbia Cancer Agency →